Tag: Cystic Fibrosis
Lumacaftor-Ivacaftor Aids Cystic Fibrosis in Real-World Setting
Improved lung function, increased BMI, reduced need for IV antibiotics seen after one year of therapy
Anaphylactic Reactions Tied to PICC Insertion With Magnetic Tip
Anaphylactic, anaphylactoid reactions linked to PICC insertion using Sherlock tip locating system
Key Cystic Fibrosis Pathogens Reduced With Ivacaftor Use
Ivacaftor use linked to reductions in P. aeruginosa rates, prevalence of S. aureus, Aspergillus species
Adding Clinical Variables Aids in Lung Allocation for Transplants
New variables ID the sickest waitlist candidates with cystic fibrosis, chronic obstructive pulmonary disease
FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12
Symdeko previously approved for patients ≥12 years with cystic fibrosis and certain genetic mutations
Cytomegalovirus Linked to Faster Progression of Cystic Fibrosis
Faster progression to end-stage lung disease observed among patients with CMV IgG positivity
Drug Combo Tolerated in Younger Children With Cystic Fibrosis
Lumacaftor/ivacaftor safe in children ages 2 to 5 with cystic fibrosis homozygous for F508del-CFTR
Inhaling Hypertonic Saline May Aid Infants With Cystic Fibrosis
The preventive treatment is safe and may provide clinical benefits in first year of life
Triple Combo Regimens May Address Cause of Cystic Fibrosis
Promising results for VX-659-, VX-445-tezacaftor-ivacaftor for cystic fibrosis with mutations in CFTR
Azithromycin Cuts Pulmonary Exacerbation in CF With Early Pa
Risk of pulmonary exacerbation down for children with cystic fibrosis, early Pseudomonas aeruginosa
